Advanz Partners With Eisai For Zonisamide

In Europe, The Middle East, Russia And Australia

 
• By Akriti Seth

Advanz has entered into an agreement with Eisai to acquire rights to its Zonegran zonisamide brand in Europe, the Middle East, Russia and Australia. Advanz said the move was “in keeping with our strategic growth plans” after the company was recently acquired by Nordic Capital in an $846m deal. 

partnership
Advanz pharma and Eisai partner for zonisamide’s European, Middle Eastern, Russian and Australian rights • Source: Alamy

More from Deals

More from Business